Tian Zhang

Adjunct Associate Professor in the Department of Medicine

Medicine, Medical Oncology

tian.zhang2@duke.edu

DUMC 103861, Durham, NC 27710

Dept of Medicine, Box 103861, Durham, NC 27710

More About This Person

At a Glance

Credentials
1. Education

Academic Experience

Expertise

Research
1. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition

Professional Activities

Selected Grants

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Clinical TrialSignificant Contributor · Awarded by National Institutes of Health · 2014 - 2023

Predicting patient-specific responses to personalize androgen deprivation therapy for prostate cancer

ResearchPrincipal Investigator · Awarded by H. Lee Moffitt Cancer Center & Research Institute · 2019 - 2022

Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer

ResearchPrincipal Investigator · Awarded by V Foundation for Cancer Research · 2016 - 2022

The impact of genetic diversity among Akkermansia strains on the effectivenes of immune checkpoint inhibitors in cancer immunotherapies

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2020 - 2022

A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN (VBIR) FOR PROSTATE CANCER (PF-06753512)

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2016 - 2021

Advancing Cancer Care in the Rural Southeast: Delivering Novel Therapies In Our Community Cancer Centers

ResearchCollaborator · Awarded by V Foundation for Cancer Research · 2019 - 2021

Validation of Prostate Cancer Stem Cell Model in First and Second Line Hormone Therapy

ResearchPrincipal Investigator · Awarded by H. Lee Moffitt Cancer Center & Research Institute · 2018 - 2021

Phase II study of AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma

Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2016 - 2021

Immune correlates of immunotherapy responses in renal cell carcinoma

ResearchPrincipal Investigator · Awarded by Kidney Cancer Association · 2019 - 2021

A Phase I/II open label multicenter study of the safety and efficacy of LAG525 single agent in combination with PDR001 adminitered to patients

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2015 - 2021

A Phase 1b, open label, prospective, non-randomized,single center study of conditional lethalithy to copper as a therapeutic modality in prostate cancer

Clinical TrialPrincipal Investigator · Awarded by Cantex Pharmaceuticals, Inc. · 2017 - 2021

Defining the Relevant Immune Checkpoints Expressed on Metastatic Prostate Cancer Circulating Tumor Cells

ResearchCo-Principal Investigator · Awarded by Janssen Research & Development, LLC · 2016 - 2021

An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2017 - 2020

A first in human study of repeat dosing with REGN2810 a fully human antibody to programmed death - 1 (PD-1) as single therapy and in combination with selected

Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2016 - 2020

MM-310-01-01-01: A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients with Solid Tumors

Clinical TrialPrincipal Investigator · Awarded by Merrimack Pharmaceuticals · 2017 - 2020

A Retrospective Study to Evaluate the Clinical Effectiveness of the OmniSeq Immune Advance Test to Predict Response to Checkpoint Inhibitors

ResearchPrincipal Investigator · Awarded by OmniSeq, Inc · 2017 - 2019

A study is to develop a retrospective database to study the PGDx TMB +MSI assay associated with clinical responses to immune checkpoint inhibitors (CPIs)

ResearchPrincipal Investigator · Awarded by Personal Genome Diagnostics, Inc. · 2017 - 2019

Retrospective analysis of docetaxel in castration sensitive setting

ResearchPrincipal Investigator · Awarded by H. Lee Moffitt Cancer Center & Research Institute · 2017 - 2019